Analysts Set Sarepta Therapeutics Inc (SRPT) PT at $189.88
Sarepta Therapeutics Inc (NASDAQ:SRPT) has been given an average recommendation of “Buy” by the twenty-eight ratings firms that are currently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, twenty-three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $189.88.
SRPT has been the subject of several analyst reports. HC Wainwright set a $267.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Wednesday, July 18th. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, August 24th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Sarepta Therapeutics in a report on Tuesday, June 19th. Bank of America initiated coverage on shares of Sarepta Therapeutics in a report on Friday, September 14th. They issued a “buy” rating and a $199.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, July 6th.
SRPT stock opened at $130.50 on Wednesday. Sarepta Therapeutics has a 52 week low of $46.07 and a 52 week high of $176.50. The company has a debt-to-equity ratio of 0.62, a current ratio of 10.88 and a quick ratio of 9.89. The firm has a market cap of $10.73 billion, a price-to-earnings ratio of -79.57 and a beta of 1.15.
In related news, SVP David T. Howton sold 50,000 shares of Sarepta Therapeutics stock in a transaction dated Monday, July 16th. The shares were sold at an average price of $136.46, for a total transaction of $6,823,000.00. Following the completion of the sale, the senior vice president now owns 37,967 shares in the company, valued at approximately $5,180,976.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Douglas S. Ingram acquired 16,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 15th. The shares were bought at an average price of $125.26 per share, with a total value of $2,004,160.00. Following the acquisition, the chief executive officer now directly owns 399,250 shares in the company, valued at $50,010,055. The disclosure for this purchase can be found here. Company insiders own 7.90% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in SRPT. Clarus Wealth Advisors bought a new stake in Sarepta Therapeutics during the 2nd quarter valued at about $124,000. Rockefeller Capital Management L.P. bought a new stake in Sarepta Therapeutics during the 2nd quarter valued at about $162,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in Sarepta Therapeutics during the 2nd quarter valued at about $185,000. Keybank National Association OH purchased a new position in Sarepta Therapeutics during the 2nd quarter valued at about $206,000. Finally, Kovack Advisors Inc. purchased a new position in Sarepta Therapeutics during the 2nd quarter valued at about $217,000. Institutional investors own 89.99% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
See Also: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.